Bladder cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• EHR Integrated Remote Patient Monitoring to Reduce Readmission for Patients With Bladder Cancer Undergoing Cystectomy

  NCT07912034· University of Michigan Rogel Cancer Center· Source

• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Janssen Research & Development, LLC· Source

• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Janssen Research & Development, LLC· Source

• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Merck Sharp & Dohme LLC· Source

• A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

  NCT07309445· Janssen Research & Development, LLC· Source

• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Janssen Research & Development, LLC· Source

• Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Janssen Research & Development, LLC· Source

• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· National Cancer Institute (NCI)· Source

• Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

  NCT07187635· Tianjin Medical University Second Hospital· Source

• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

  NCT05567185· Janssen Pharmaceutical K.K.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Organoids 2
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 4
• Sequence Analysis, RNA 1
• Proteomics 3
• Flow Cytometry 14
• Immunohistochemistry 18
• Xenograft Model Antitumor Assays 17
• Magnetic Resonance Imaging 1
• Cohort Studies 20
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.